Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C.
about
Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus.Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection.Pharmacogenetics of ribavirin-induced anemia in HCV patients.Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C.
P2860
Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Comparative safety study on se ...... erapy for chronic hepatitis C.
@en
Comparative safety study on se ...... erapy for chronic hepatitis C.
@nl
type
label
Comparative safety study on se ...... erapy for chronic hepatitis C.
@en
Comparative safety study on se ...... erapy for chronic hepatitis C.
@nl
prefLabel
Comparative safety study on se ...... erapy for chronic hepatitis C.
@en
Comparative safety study on se ...... erapy for chronic hepatitis C.
@nl
P2093
P2860
P356
P1476
Comparative safety study on se ...... erapy for chronic hepatitis C.
@en
P2093
Akira Kawano
Eiichi Ogawa
Eiji Kajiwara
Hideyuki Nomura
Jun Hayashi
Kazufumi Dohmen
Kazuhiro Kotoh
Kazuhiro Takahashi
Koichi Azuma
Kyushu University Liver Disease Study (KULDS) Group
P2860
P304
P356
10.1111/JGH.12945
P577
2015-08-01T00:00:00Z